Paul Ruff

Paul Ruff

Auto-generated profile, based on publicly available information

Paul Ruff

Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LSLara Stein
Lara Stein
MUMargaret I. Urban
Margaret I. Urban
DODianne O'COnnell
Dianne O'COnnell
XYXue Qin Yu
Xue Qin Yu
VBValerie Beral
Valerie Beral
FSFreddy Sitas
Freddy Sitas

25 February 2009 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
PRPaul Ruff
Paul Ruff
DVD. A. Vorobiof
D. A. Vorobiof
JJJ. P. Jordaan
J. P. Jordaan
GDG. S. Demetriou
G. S. Demetriou
SMS. D. Moodley
S. D. Moodley
LBL. J. Burgess
L. J. Burgess

2 March 2007 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
FSFreddy Sitas
Freddy Sitas
MUMargaret Urban
Margaret Urban
LSLara Stein
Lara Stein
VBValerie Beral
Valerie Beral
PRPaul Ruff
Paul Ruff
AWAnna-Lise Williamson
Anna-Lise Williamson
Human papillomavirus type 16 (HPV-16) infection is an important cause of cervical cancer, other anogenital cancers and, possibly, some oral and pharyngeal cancers. The association of HPV-16 with oesophageal and with prostate cancers has not been firmly established. We analysed sera from 3,757 HIV seronegative black South Africans using an anti-HPV IgG enzyme-linked immunosorbent assay (ELISA). The subjects were recruited from 1995 to 2000 as part of an ongoing cancer case control study. Cases were patients with newly diagnosed cancers of the cervix (n = 946), other anogenital organs (n = 80), the oral cavity and pharynx (n = 102), the oesophagus (n = 369) or the prostate (n = 205). The comparison group consisted of 2,055 age and sex-matched patients randomly selected from the same data base, diagnosed at the same hospitals, but with a vascular disease or with a cancer unrelated to HPV infection. Subjects' sera were randomly and blindly allocated onto ELISA plates. Optical density (OD) levels of anti-HPV-16 IgG of > 0.45 and ≥ 0.767 were taken to be cut-offs for negative, medium and high antibody levels. After adjustment for potential confounders, cancer types that showed a statistically significant association with increased anti-HPV-16 IgG antibody (Ab) levels were cancer of the cervix (OR for medium Ab levels = 1.6, and for high = 2.4, p < 0.0001), cancers of other anogenital organs (OR for medium or high Ab levels = 2.5, p = 0.002), and cancer of the oesophagus (OR for medium Ab = 1.3, and high Ab levels = 1.6 p = 0.002). Cancers of the oral cavity and pharynx showed a borderline significant association in the unadjusted model (p = 0.05) but after adjustment for confounding the trend in relation to Ab levels was positive but not statistically significant (OR for medium Ab = 1.1, and high Ab = 1.5 p = 0.13). Prostate cancer was not associated with HPV-16 seropositivity (OR for medium Ab level = 1.4, and for high Ab level = 1.3, p = 0.3). If there is indeed an association between HPV-16 and oesophageal and possibly also some oral cavity and pharyngeal cancers, then emerging HPV vaccines may also reduce, at least in part, the incidence of these leading cancer types.

1 January 2018 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
PRPaul Ruff
Paul Ruff
ECEric Van Cutsem
Eric Van Cutsem
RLRadek Lakomy
Radek Lakomy
JPJana Prausova
Jana Prausova
GHGuy A. van Hazel
Guy A. van Hazel
DPDemetris Papamichael
Demetris Papamichael

1 June 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
CCChantelle Carbonell
Chantelle Carbonell
AAAbisola Adegbulugbe
Abisola Adegbulugbe
WCWinson Cheung
Winson Cheung
PRPaul Ruff
Paul Ruff
Quality improvement (QI) programs have rapidly grown in health care over recent years. Despite increasing evidence of successful QI initiatives resulting in improved outcomes, the adoption and implementation of QI programs remain a challenge worldwide. This paper briefly describes political and administrative barriers that impede the implementation of QI programs, including political and ideological factors, socioeconomic and educational barriers, and barriers related to data collection, privacy, and security. Key political and administrative barriers identified include resource limitations due to inadequate public funding, stringent laws, and change resistance. Potential solutions include support and commitment from regional and national authorities, consultation of all involved parties during QI program development, and financial incentives. The barrier of limited resources is starker among low- and middle-income countries (LMICs) compared with high-income countries (HICs) due to the absence of adequate infrastructure, personnel equipped with QI-oriented skills, and analytical technology. Solutions that have facilitated QI programs in some LMICs include outreach and collaboration with other health centers and established QI programs in HICs. The lack of QI-specific training and education in medical curricula challenges QI implementation but can be mitigated through the provision of QI promotion webinars, QI-specific project opportunities, and formalized QI training modules. Finally, barriers related to data collection, privacy, and security include laws hindering the availability of quality data, inefficient data collection and processes, and outdated clinical information systems. Access to high-quality data, organized record-keeping, and alignment of data collection processes will help alleviate these barriers to QI program implementation. The multidimensional nature of these barriers means that proposed solutions will require coordination from multiple stakeholders, government support, and leaders across multiple fields.

1 January 2015 in European Journal of Cancer
Verified
Journal Article
Open access
PRPaul Ruff
Paul Ruff
DFDavid R. Ferry
David R. Ferry
RLRadek Lakomỳ
Radek Lakomỳ
JPJana Prausová
Jana Prausová
GHGuy A. Van Hazel
Guy A. Van Hazel
ECEric Van Cutsem
Eric Van Cutsem
Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate. The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n=612) or placebo (n=614). Hazard ratios (HR) by 6-month time period were estimated using a piecewise Cox proportional hazard model. Severity of adverse events (AEs) was graded using National Cancer Institute Common Terminology Criteria, version 3.0. The estimated probabilities of survival were 38.5% versus 30.9% at 18 months, 28.0% versus 18.7% at 24 months and 22.3% versus 12.0% at 30 months, for the aflibercept- and placebo-treated arms, respectively. The proportional improvement in the HR over time was consistent with the survival probability results; survival at 24 months was improved by 50% and almost doubled at 30 months. The majority of worst-grade AEs occurred within the first four cycles of treatment and in a small percent of treatment cycles and were mostly reversible. Common chemotherapy- and anti-vascular epithelial growth factor (VEGF)-associated AEs occurred rarely and in a small proportion of cycles with the majority being of single occurrence. The addition of aflibercept to FOLFIRI showed a continued and persistent improvement in overall survival over time in patients with mCRC. Although grade 3-4 AEs were more frequent in the aflibercept arm, they occurred in early treatment cycles and decreased sharply following initial presentation.